Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Merck Sharp & Dhome (Australia) Pty. Ltd. | UNKNOWN |
| Christian Medical College, Vellore, India | OTHER |
| Tan Tock Seng Hospital | OTHER |
| Royal Brisbane and Women's Hospital |
Not provided
Not provided
Not provided
Not provided
Infection with bacteria or fungi can be deadly. Often, these types of infections can lead to an increase in the severity of illness requiring intensive care unit (ICU) admission, prolonged duration of treatment and further risks associated with additional infections and superinfections. These are also called hospital acquired secondary infections. Patients who contract COVID-19 and require an ICU admission are at increased risk of contracting these secondary infections, and receive certain medications that can lower your body's immune response. In COVID-19 patients who require these treatments, it is unclear what affect these medications can have on developing an additional infection as well as the rate of recovery/survival. This study is evaluating the effect these medications have on the development of secondary infections and rate of survival of COVID-19 patients that have been admitted to ICUs.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Previously admitted COVID-19 patients in intensive care units | Infectious Diseases Physicians from participating hospitals will identify patients with COVID-19 admitted to their hospital who had an intensive care unit stay during the first 60 days after hospital admission. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Previously admitted COVID-19 patients in intensive care units | Other | Exposure: this is a retrospective, observational study that does not include an intervention. Data collected for this study will be from previously hospitalized COVID-19 patients who had an intensive care unit stay during their admission |
| Measure | Description | Time Frame |
|---|---|---|
| Describe the incidence, management and outcomes of secondary infections in COVID-19 patients admitted to intensive care units | Data collected from medical records of patients will include demographics, medical history, details of bacterial and fungal infections in the first 60 days after admission (includes aetiological pathogen, sample isolated from and antimicrobial susceptibility), treatment received for COVID-19 with antiviral or immunomodulatory therapy and disposition at 60 days from hospital admission | Within the first 60 days of hospital admission |
| Compare clinical and microbiological outcomes based on treatment appropriateness in COVID-19 patients admitted to intensive care units | Data collected from medical records of patients will include demographics, medical history, details of bacterial and fungal infections in the first 60 days after admission (includes aetiological pathogen, sample isolated from and antimicrobial susceptibility), treatment received for COVID-19 with antiviral or immunomodulatory therapy and disposition at 60 days from hospital admission | Within the first 60 days of hospital admission |
| Assess the use and effect of immune suppression in COVID-19 patients admitted to intensive care units. | Data collected from medical records of patients will include demographics, medical history, details of bacterial and fungal infections in the first 60 days after admission (includes aetiological pathogen, sample isolated from and antimicrobial susceptibility), treatment received for COVID-19 with antiviral or immunomodulatory therapy and disposition at 60 days from hospital admission | Within the first 60 days of hospital admission |
Not provided
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Previously admitted COVID-19 patients admitted to Intensive Care Units
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| University of North Carolina | Chapel Hill | North Carolina | 27599 | United States | ||
| Royal Brisbane and Women's Hospital |
Not provided
| ID | Term |
|---|---|
| D000086382 | COVID-19 |
| D060085 | Coinfection |
| D001424 | Bacterial Infections |
| D009181 | Mycoses |
| ID | Term |
|---|---|
| D011024 | Pneumonia, Viral |
| D011014 | Pneumonia |
| D012141 | Respiratory Tract Infections |
| D007239 | Infections |
Not provided
Not provided
| ID | Term |
|---|---|
| D007362 | Intensive Care Units |
| ID | Term |
|---|---|
| D006757 | Hospital Units |
| D006268 | Health Facilities |
| D005159 | Health Care Facilities Workforce and Services |
Not provided
Not provided
| OTHER_GOV |
| Siriraj Hospital | OTHER |
| University of North Carolina, Chapel Hill | OTHER |
Not provided
Not provided
Not provided
|
| Herston |
| Queensland |
| 4029 |
| Australia |
| Christian Medical College | Vellore | 632004 | India |
| Tan Tock Seng Hospital | Singapore | Singapore |
| Siriraj Hospital | Bangkok | Thailand |
| D014777 |
| Virus Diseases |
| D018352 | Coronavirus Infections |
| D003333 | Coronaviridae Infections |
| D030341 | Nidovirales Infections |
| D012327 | RNA Virus Infections |
| D008171 | Lung Diseases |
| D012140 | Respiratory Tract Diseases |
| D001423 | Bacterial Infections and Mycoses |